Back to top

Image: Bigstock

ImmunoGen, Inc.

Read MoreHide Full Article

ImmunoGen reported mixed first-quarter results, wherein earnings missed estimates but sales surpassed the same. The company has made a significant progress with regard to its lead ovarian cancer candidate, mirvetuximab soravtansine. Successful development and subsequent approval of the candidate will be a huge boost to the company as the ovarian cancer market has immense potential. The company has collaborations with big healthcare companies which not only validate its technology but also provides it with funds in the form of milestone and royalty payments. However, ImmunoGen is heavily dependent on its lead candidate, mirvetuximab soravtansine. Hence, any kind of development or a regulatory setback could hamper the stock. The ovarian cancer space being competitive is also a matter of concern for the company. The company’s shares have outperformed the broader industry so far this year.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


ImmunoGen, Inc. (IMGN) - free report >>

Published in